A Phase 3 interventional study of amlodipine and telmisartan in Hypertension, sponsored by Boehringer Ingelheim. Completed at 137 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-05-20.
Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 99 studies testing telmisartan in Hypertension — 1 open to participants now, 1 under way, none of them phase 3. Telmisartan · Hypertension.
Among the 99 studies testing telmisartan in Hypertension, this one is the 14th largest by enrollment, is one of 4 that started in 2009, is one of 40 in phase 3, and was the 36th registered.
6,128 studies on the registry are indexed under Hypertension; 911 are open to participants now.
Browse Hypertension studies →1 of the 99 studies testing telmisartan in Hypertension is open now, in 1 country. Recruiting first, the newest first:
Chong Kun Dang Pharmaceutical · Sites in Korea, Republic of
Ages 19–75
By country, each count listing its studies:
Telmisartan: first FDA approval 1998 (MICARDIS), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →
Of the 556 Hypertension studies recruiting now, 262 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 137 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
99 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 16 · Phase 2 5 · Phase 3 40 · Phase 4 32
First in 1997; this study’s year is marked. 4 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 858 is above the median of 100 across 4,585 interventional studies indexed under Hypertension.
Median enrollment 184 across the 99 interventional studies. Of the 91 that completed or were terminated, 14 (15%) have results posted.
This tab as a report to print or save as PDF → With an account.
75 of 99 have an industry lead sponsor. The 10 most frequent:
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
122 studies in Hypertension by Boehringer Ingelheim: 1 open now, 1 under way, 1 of them phase 3. Of 120 finished, 41 (34%) have results posted.
Among the 122 studies in Hypertension by Boehringer Ingelheim, this one is the 17th largest by enrollment of the 74 interventional ones that give a count, is one of 8 that started in 2009, is one of 43 in phase 3, and was the 42nd registered.
Boehringer Ingelheim’s Hypertension studies by the year they started, since 1995.
None of the studies under way reaches primary completion within a year.
Among the 99 studies testing telmisartan in Hypertension, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Boehringer Ingelheim’s 122 in Hypertension:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of this trial is to demonstrate that following eight weeks of treatment the FDC of telmisartan 80 mg plus amlodipine 10 mg (T80/A10) is superior as first line therapy in reducing mean seated trough cuff Systolic Blood Pressure [SBP] compared to the monotherapies of telmisartan 80 mg (T80) and amlodipine 10 mg (A10) in patients with severe hypertension. A key secondary objective is to identify the duration of treatment required to demonstrate the superiority of the FDC over both of the monotherapies.
Inclusion criteria
Exclusion criteria Mean in-clinic seated cuff SBP >/= 200 mmHg and/or Diastolic Blood Pressure [DBP] >/= 95 mmHg
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
telmisartan and amlodipine used in combination vs amlodipine or telmisartan
Drug: telmisartan and amlodipine
telmisartan and amlodipine used in combination vs amlodipine or telmisartan
Drug: amlodipine
telmisartan and amlodipine used in combination vs amlodipine or telmisartan
Drug: telmisartan
amlodipine 5mg for the first 2w then force titration to Amlodipine 10mg for remaining 6 w
telmisartan 80mg for the 8w, no titration required
Drug pages: Telmisartan · Amlodipine
telmisartan 80 and amlodipine 5mg for the first 2 weeks, then force titrated to telmisartan 80mg and amlodipine 10mg for the remaining 6w
Change From Baseline in Trough Seated Systolic Blood Pressure (SBP) at Week 8
Overall mean reduction from a common mean baseline in SBP
Time frame: baseline and week 8
Change From Baseline in Trough Seated Systolic Blood Pressure at Week 6
Overall mean reduction from a common mean baseline in SBP
Time frame: baseline and week 6
Change From Baseline in Trough Seated Systolic Blood Pressure at Week 4
Overall mean reduction from a common mean baseline in SBP
Time frame: baseline and week 4
Change From Baseline in Trough Seated Systolic Blood Pressure at Week 2
Overall mean reduction from a common mean baseline in SBP
Time frame: baseline and week 2
Change From Baseline in Trough Seated Systolic Blood Pressure at Week 1
Overall mean reduction from a common mean baseline in SBP
Time frame: baseline and week 1
Change From Baseline in Trough Seated Diastolic Blood Pressure (DBP) at Week 8
Overall mean reduction from a common mean baseline in DBP
Time frame: baseline and week 8
Change From Baseline in Trough Seated Diastolic Blood Pressure at Week 6
Overall mean reduction from a common mean baseline in DBP
Time frame: baseline and week 6
Change From Baseline in Trough Seated Diastolic Blood Pressure at Week 4
Overall mean reduction from a common mean baseline in DBP
Time frame: baseline and week 4
Change From Baseline in Trough Seated Diastolic Blood Pressure at Week 2
Overall mean reduction from a common mean baseline in DBP
Time frame: baseline and week 2
Change From Baseline in Trough Seated Diastolic Blood Pressure at Week 1
Overall mean reduction from a common mean baseline in DBP
Time frame: baseline and week 1
Patients Achieving Diastolic Blood Pressure Control at Week 1
Diastolic Blood Pressure Control is defined as achieving DBP \< 90mmHg
Time frame: week 1
Patients Achieving Diastolic Blood Pressure Control at Week 2
DBP \< 90 mmHg
Time frame: week 2
Patients Achieving Blood Pressure Control at Week 1
Blood Pressure Control is defined as achieving SBP\< 140 mmHg and DBP \< 90mmHg
Time frame: week 1
Patients Achieving Blood Pressure Control at Week 2
SBP \< 140 mmHg and DBP \< 90 mmHg
Time frame: week 2
Patients Achieving Diastolic Blood Pressure Response at Week 1
Diastolic Blood Pressure Response is defined as achieving DBP \< 90 mmHg or a reduction of \>= 10 mmHg
Time frame: baseline, week 1
Patients Achieving Diastolic Blood Pressure Response at Week 2
DBP \< 90 mmHg or reduction of \>= 10 mmHg
Time frame: baseline, week 2
Patients Achieving Systolic Blood Pressure Response at Week 1
Systolic Blood Pressure Response Control is defined as achieving SBP \< 140 mmHg or a reduction of \>= 15 mmHg
Time frame: baseline, week 1
Patients Achieving Systolic Blood Pressure Response at Week 2
SBP \< 140 mmHg or reduction of \>= 15 mmHg
Time frame: baseline, week 2
Number of Patients Achieving Various Blood Pressure Response Levels at Week 1
Optimal: SBP\<120 and DBP\< 80; Normal: 120\<=SBP\<130 and 80\<= DBP\<85; High normal: 130\<=SBP\<140 and 85\<=DBP\<90; High: SBP\>=140 or DBP\>=90
Time frame: week 1
Number of Patients Achieving Various Blood Pressure Response Levels at Week 2
Optimal: SBP\<120 and DBP\< 80; Normal: 120\<=SBP\<130 and 80\<= DBP\<85; High normal: 130\<=SBP\<140 and 85\<=DBP\<90; High: SBP\>=140 or DBP\>=90
Time frame: week 2
Patients Achieving Diastolic Blood Pressure Control at Week 4
DBP \< 90 mmHg
Time frame: week 4
Patients Achieving Diastolic Blood Pressure Control at Week 6
DBP \< 90 mmHg
Time frame: week 6
Patients Achieving Diastolic Blood Pressure Control at Week 8
DBP \< 90 mmHg
Time frame: week 8
Patients Achieving Blood Pressure Control at Week 4
SBP \< 140 mmHg and DBP \< 90 mmHg
Time frame: week 4
Patients Achieving Blood Pressure Control at Week 6
SBP \< 140 mmHg and DBP \< 90 mmHg
Time frame: week 6
Patients Achieving Blood Pressure Control at Week 8
SBP \< 140 mmHg and DBP \< 90 mmHg
Time frame: week 8
Patients Achieving Diastolic Blood Pressure Response at Week 4
DBP \< 90 mmHg or reduction of \>= 10 mmHg
Time frame: baseline, week 4
Patients Achieving Diastolic Blood Pressure Response at Week 6
DBP \< 90 mmHg or reduction of \>= 10 mmHg
Time frame: baseline, week 6
Patients Achieving Diastolic Blood Pressure Response at Week 8
DBP \< 90 mmHg or reduction of \>= 10 mmHg
Time frame: baseline, week 8
Patients Achieving Systolic Blood Pressure Response at Week 4
SBP \< 140 mmHg or reduction of \>= 15 mmHg
Time frame: baseline, week 4
Patients Achieving Systolic Blood Pressure Response at Week 6
SBP \< 140 mmHg or reduction of \>= 15 mmHg
Time frame: baseline, week 6
Patients Achieving Systolic Blood Pressure Response at Week 8
SBP \< 140 mmHg or reduction of \>= 15 mmHg
Time frame: baseline, week 8
Patients Achieving Normal Blood Pressure Response at Week 4
Optimal: SBP\<120 and DBP\< 80; Normal: 120\<=SBP\<130 and 80\<= DBP\<85; High normal: 130\<=SBP\<140 and 85\<=DBP\<90; High: SBP\>=140 or DBP\>=90
Time frame: week 4
Patients Achieving Normal Blood Pressure Response at Week 6
Optimal: SBP\<120 and DBP\< 80; Normal: 120\<=SBP\<130 and 80\<= DBP\<85; High normal: 130\<=SBP\<140 and 85\<=DBP\<90; High: SBP\>=140 or DBP\>=90
Time frame: week 6
Patients Achieving Normal Blood Pressure Response at Week 8
Optimal: SBP\<120 and DBP\< 80; Normal: 120\<=SBP\<130 and 80\<= DBP\<85; High normal: 130\<=SBP\<140 and 85\<=DBP\<90; High: SBP\>=140 or DBP\>=90
Time frame: week 8
| Milestone | T80+A10 | Telmisartan 80 mg | Amlodipine 10 mg |
|---|---|---|---|
| Started | 421 | 217 | 220 |
| Completed | 401 | 195 | 202 |
| Not completed | 20 | 22 | 18 |
| Withdrew: Adverse event | 9 | 6 | 7 |
| Withdrew: Protocol violation | 0 | 1 | 0 |
| Withdrew: Lost to follow-up | 2 | 0 | 1 |
| Withdrew: Withdrawal by subject | 4 | 8 | 6 |
| Withdrew: Lack of efficacy | 0 | 4 | 3 |
| Withdrew: Other | 5 | 3 | 1 |
Overall mean reduction from a common mean baseline in SBP
| mmHg (millimeters of mercury) | T80+A10 | Telmisartan 80 mg | Amlodipine 10 mg |
|---|---|---|---|
| Change From Baseline in Trough Seated Systolic Blood Pressure (SBP) at Week 8 | -47.5 ± 0.69 | -36.9 ± 0.96 | -43.2 ± 0.95 |
Overall mean reduction from a common mean baseline in SBP
| mmHg (millimeters of mercury) | T80+A10 | Telmisartan 80 mg | Amlodipine 10 mg |
|---|---|---|---|
| Change From Baseline in Trough Seated Systolic Blood Pressure at Week 6 | -46.9 ± 0.73 | -36.3 ± 1.01 | -42.1 ± 1.01 |
Overall mean reduction from a common mean baseline in SBP
| mmHg (millimeters of mercury) | T80+A10 | Telmisartan 80 mg | Amlodipine 10 mg |
|---|---|---|---|
| Change From Baseline in Trough Seated Systolic Blood Pressure at Week 4 | -44.5 ± 0.73 | -34.4 ± 1.01 | -39.8 ± 1.01 |
Overall mean reduction from a common mean baseline in SBP
| mmHg (millimeters of mercury) | T80+A5 | Telmisartan 80 mg | Amlodipine 5 mg |
|---|---|---|---|
| Change From Baseline in Trough Seated Systolic Blood Pressure at Week 2 | -37.9 ± 0.71 | -30.1 ± 0.97 | -33.3 ± 0.98 |
Overall mean reduction from a common mean baseline in SBP
| mmHg (millimeters of mercury) | T80+A5 | Telmisartan 80 mg | Amlodipine 5 mg |
|---|---|---|---|
| Change From Baseline in Trough Seated Systolic Blood Pressure at Week 1 | -31.9 ± 0.72 | -25.4 ± 0.99 | -28.6 ± 0.99 |
Overall mean reduction from a common mean baseline in DBP
| mmHg (millimeters of mercury) | T80+A10 | Telmisartan 80 mg | Amlodipine 10 mg |
|---|---|---|---|
| Change From Baseline in Trough Seated Diastolic Blood Pressure (DBP) at Week 8 | -18.7 ± 0.41 | -13.8 ± 0.58 | -16.3 ± 0.58 |
Overall mean reduction from a common mean baseline in DBP
| mmHg (millimeters of mercury) | T80+A10 | Telmisartan 80 mg | Amlodipine 10 mg |
|---|---|---|---|
| Change From Baseline in Trough Seated Diastolic Blood Pressure at Week 6 | -18.3 ± 0.41 | -13.5 ± 0.57 | -15.7 ± 0.57 |
Overall mean reduction from a common mean baseline in DBP
| mmHg (millimeters of mercury) | T80+A10 | Telmisartan 80 mg | Amlodipine 10 mg |
|---|---|---|---|
| Change From Baseline in Trough Seated Diastolic Blood Pressure at Week 4 | -17.0 ± 0.43 | -12.1 ± 0.60 | -14.2 ± 0.60 |
Overall mean reduction from a common mean baseline in DBP
| mmHg (millimeters of mercury) | T80+A5 | Telmisartan 80 mg | Amlodipine 5 mg |
|---|---|---|---|
| Change From Baseline in Trough Seated Diastolic Blood Pressure at Week 2 | -13.2 ± 0.40 | -10.4 ± 0.56 | -11.4 ± 0.56 |
Overall mean reduction from a common mean baseline in DBP
| mmHg (millimeters of mercury) | T80+A5 | Telmisartan 80 mg | Amlodipine 5 mg |
|---|---|---|---|
| Change From Baseline in Trough Seated Diastolic Blood Pressure at Week 1 | -10.9 ± 0.37 | -8.2 ± 0.50 | -9.6 ± 0.50 |
Diastolic Blood Pressure Control is defined as achieving DBP \< 90mmHg
| participants | T80+A5 | Telmisartan 80 mg | Amlodipine 5 mg |
|---|---|---|---|
| Controlled | 147 | 61 | 64 |
| Not Controlled | 240 | 146 | 143 |
DBP \< 90 mmHg
| participants | T80+A5 | Telmisartan 80 mg | Amlodipine 5 mg |
|---|---|---|---|
| Controlled | 205 | 87 | 91 |
| Not Controlled | 200 | 125 | 121 |
Blood Pressure Control is defined as achieving SBP\< 140 mmHg and DBP \< 90mmHg
| participants | T80+A5 | Telmisartan 80 mg | Amlodipine 5 mg |
|---|---|---|---|
| Controlled | 54 | 16 | 15 |
| Not Controlled | 333 | 191 | 192 |
SBP \< 140 mmHg and DBP \< 90 mmHg
| participants | T80+A5 | Telmisartan 80 mg | Amlodipine 5 mg |
|---|---|---|---|
| Controlled | 88 | 30 | 28 |
| Not Controlled | 317 | 182 | 184 |
Diastolic Blood Pressure Response is defined as achieving DBP \< 90 mmHg or a reduction of \>= 10 mmHg
| participants | T80+A5 | Telmisartan 80 mg | Amlodipine 5 mg |
|---|---|---|---|
| Controlled | 232 | 95 | 100 |
| Not Controlled | 155 | 112 | 107 |
DBP \< 90 mmHg or reduction of \>= 10 mmHg
| participants | T80+A5 | Telmisartan 80 mg | Amlodipine 5 mg |
|---|---|---|---|
| Controlled | 289 | 123 | 128 |
| Not Controlled | 116 | 89 | 84 |
Systolic Blood Pressure Response Control is defined as achieving SBP \< 140 mmHg or a reduction of \>= 15 mmHg
| participants | T80+A5 | Telmisartan 80 mg | Amlodipine 5 mg |
|---|---|---|---|
| Controlled | 338 | 164 | 173 |
| Not Controlled | 49 | 43 | 34 |
SBP \< 140 mmHg or reduction of \>= 15 mmHg
| participants | T80+A5 | Telmisartan 80 mg | Amlodipine 5 mg |
|---|---|---|---|
| Controlled | 387 | 169 | 189 |
| Not Controlled | 18 | 43 | 23 |
Optimal: SBP\<120 and DBP\< 80; Normal: 120\<=SBP\<130 and 80\<= DBP\<85; High normal: 130\<=SBP\<140 and 85\<=DBP\<90; High: SBP\>=140 or DBP\>=90
| participants | T80+A5 | Telmisartan 80 mg | Amlodipine 5 mg |
|---|---|---|---|
| Optimal | 3 | 0 | 0 |
| Normal | 9 | 3 | 3 |
| High Normal | 42 | 13 | 12 |
| High | 333 | 191 | 192 |
Optimal: SBP\<120 and DBP\< 80; Normal: 120\<=SBP\<130 and 80\<= DBP\<85; High normal: 130\<=SBP\<140 and 85\<=DBP\<90; High: SBP\>=140 or DBP\>=90
| participants | T80+A5 | Telmisartan 80 mg | Amlodipine 5 mg |
|---|---|---|---|
| Optimal | 6 | 0 | 0 |
| Normal | 21 | 7 | 5 |
| High Normal | 61 | 23 | 23 |
| High | 317 | 182 | 184 |
DBP \< 90 mmHg
| participants | T80+A10 | Telmisartan 80 mg | Amlodipine 10 mg |
|---|---|---|---|
| Controlled | 268 | 106 | 109 |
| Not Controlled | 124 | 106 | 94 |
DBP \< 90 mmHg
| participants | T80+A10 | Telmisartan 80 mg | Amlodipine 10 mg |
|---|---|---|---|
| Controlled | 290 | 110 | 128 |
| Not Controlled | 104 | 102 | 77 |
DBP \< 90 mmHg
| participants | T80+A10 | Telmisartan 80 mg | Amlodipine 10 mg |
|---|---|---|---|
| Controlled | 291 | 112 | 131 |
| Not Controlled | 103 | 100 | 74 |
SBP \< 140 mmHg and DBP \< 90 mmHg
| participants | T80+A10 | Telmisartan 80 mg | Amlodipine 10 mg |
|---|---|---|---|
| Controlled | 161 | 49 | 53 |
| Not Controlled | 231 | 163 | 150 |
SBP \< 140 mmHg and DBP \< 90 mmHg
| participants | T80+A10 | Telmisartan 80 mg | Amlodipine 10 mg |
|---|---|---|---|
| Controlled | 196 | 54 | 77 |
| Not Controlled | 198 | 158 | 128 |
SBP \< 140 mmHg and DBP \< 90 mmHg
| participants | T80+A10 | Telmisartan 80 mg | Amlodipine 10 mg |
|---|---|---|---|
| Controlled | 199 | 51 | 73 |
| Not Controlled | 196 | 161 | 132 |
DBP \< 90 mmHg or reduction of \>= 10 mmHg
| participants | T80+A10 | Telmisartan 80 mg | Amlodipine 10 mg |
|---|---|---|---|
| Controlled | 339 | 132 | 151 |
| Not Controlled | 53 | 80 | 61 |
DBP \< 90 mmHg or reduction of \>= 10 mmHg
| participants | T80+A10 | Telmisartan 80 mg | Amlodipine 10 mg |
|---|---|---|---|
| Controlled | 356 | 144 | 168 |
| Not Controlled | 38 | 68 | 37 |
DBP \< 90 mmHg or reduction of \>= 10 mmHg
| participants | T80+A10 | Telmisartan 80 mg | Amlodipine 10 mg |
|---|---|---|---|
| Controlled | 361 | 147 | 172 |
| Not Controlled | 34 | 65 | 33 |
SBP \< 140 mmHg or reduction of \>= 15 mmHg
| participants | T80+A10 | Telmisartan 80 mg | Amlodipine 10 mg |
|---|---|---|---|
| Controlled | 388 | 180 | 194 |
| Not Controlled | 4 | 32 | 9 |
SBP \< 140 mmHg or reduction of \>= 15 mmHg
| participants | T80+A10 | Telmisartan 80 mg | Amlodipine 10 mg |
|---|---|---|---|
| Controlled | 388 | 184 | 201 |
| Not Controlled | 6 | 28 | 4 |
SBP \< 140 mmHg or reduction of \>= 15 mmHg
| participants | T80+A10 | Telmisartan 80 mg | Amlodipine 10 mg |
|---|---|---|---|
| Controlled | 391 | 188 | 202 |
| Not Controlled | 4 | 24 | 3 |
Optimal: SBP\<120 and DBP\< 80; Normal: 120\<=SBP\<130 and 80\<= DBP\<85; High normal: 130\<=SBP\<140 and 85\<=DBP\<90; High: SBP\>=140 or DBP\>=90
| participants | T80+A10 | Telmisartan 80 mg | Amlodipine 10 mg |
|---|---|---|---|
| Optimal | 15 | 4 | 2 |
| Normal | 47 | 15 | 14 |
| High Normal | 99 | 30 | 37 |
| High | 231 | 163 | 150 |
Optimal: SBP\<120 and DBP\< 80; Normal: 120\<=SBP\<130 and 80\<= DBP\<85; High normal: 130\<=SBP\<140 and 85\<=DBP\<90; High: SBP\>=140 or DBP\>=90
| participants | T80+A10 | Telmisartan 80 mg | Amlodipine 10 mg |
|---|---|---|---|
| Optimal | 17 | 5 | 3 |
| Normal | 73 | 19 | 18 |
| High Normal | 106 | 30 | 56 |
| High | 198 | 158 | 128 |
Optimal: SBP\<120 and DBP\< 80; Normal: 120\<=SBP\<130 and 80\<= DBP\<85; High normal: 130\<=SBP\<140 and 85\<=DBP\<90; High: SBP\>=140 or DBP\>=90
| participants | T80+A10 | Telmisartan 80 mg | Amlodipine 10 mg |
|---|---|---|---|
| Optimal | 18 | 3 | 2 |
| Normal | 76 | 21 | 25 |
| High Normal | 105 | 27 | 46 |
| High | 196 | 161 | 132 |
Collected over First study medication intake, last study medication intake + 6 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| T80+A10 | — | 3/421 (0.7%) | 67/421 (15.9%) |
| Telmisartan 80 mg | — | 2/217 (0.9%) | 25/217 (11.5%) |
| Amlodipine 10 mg | — | 2/220 (0.9%) | 42/220 (19.1%) |
| Event | T80+A10 | Telmisartan 80 mg | Amlodipine 10 mg |
|---|---|---|---|
| Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/421 | 1/217 | 0/220 |
| Transient ischaemic attackNervous system disorders | 0/421 | 1/217 | 0/220 |
| Atrial fibrillationCardiac disorders | 0/421 | 0/217 | 1/220 |
| Atrioventricular block second degreeCardiac disorders | 0/421 | 0/217 | 1/220 |
| Diverticular perforationGastrointestinal disorders | 1/421 | 0/217 | 0/220 |
| Peridiverticular abscessInfections and infestations | 1/421 | 0/217 | 0/220 |
| Ischaemic strokeNervous system disorders | 1/421 | 0/217 | 0/220 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 1/421 | 0/217 | 0/220 |
| Event | T80+A10 | Telmisartan 80 mg | Amlodipine 10 mg |
|---|---|---|---|
| Oedema peripheralGeneral disorders | 55/421 | 8/217 | 33/220 |
| HeadacheNervous system disorders | 16/421 | 18/217 | 12/220 |
| Age, Continuous(years) | T80+A10 | Telmisartan 80 mg | Amlodipine 10 mg | Total |
|---|---|---|---|---|
| Mean | 58.0 ± 10.4 | 58.1 ± 10.2 | 58.6 ± 10.5 | 58.2 ± 10.3 |
| Age, Customized(Participants) | T80+A10 | Telmisartan 80 mg | Amlodipine 10 mg | Total |
|---|---|---|---|---|
| < 65 years | 309 | 158 | 156 | 623 |
| >= 65 years | 112 | 59 | 64 | 235 |
| Sex: Female, Male(Participants) | T80+A10 | Telmisartan 80 mg | Amlodipine 10 mg | Total |
|---|---|---|---|---|
| Female | 202 | 109 | 102 | 413 |
| Male | 219 | 108 | 118 | 445 |
| Race/Ethnicity, Customized(participants) | T80+A10 | Telmisartan 80 mg | Amlodipine 10 mg | Total |
|---|---|---|---|---|
| White | 362 | 186 | 190 | 738 |
| Black/African American | 34 | 15 | 15 | 64 |
| Asian | 20 | 14 | 14 | 48 |
| American Indian/Alaska Native | 5 | 1 | 0 | 6 |
| Hawaiian/Pacific Islander | 0 | 1 | 1 | 2 |
| Body Mass Index (BMI)(kilograms/square meter) | T80+A10 | Telmisartan 80 mg | Amlodipine 10 mg | Total |
|---|---|---|---|---|
| Mean | 30.6 ± 5.9 | 30.2 ± 5.2 | 30.7 ± 6.3 | 30.6 ± 5.8 |
| Body Mass Index Class(participants) | T80+A10 | Telmisartan 80 mg | Amlodipine 10 mg | Total |
|---|---|---|---|---|
| BMI < 25 | 63 | 31 | 35 | 129 |
| 25 <= BMI < 30 | 160 | 79 | 82 | 321 |
| BMI >= 30 | 198 | 107 | 103 | 408 |
| Race Class(participants) | T80+A10 | Telmisartan 80 mg | Amlodipine 10 mg | Total |
|---|---|---|---|---|
| Non-Black | 387 | 202 | 205 | 794 |
| Black | 34 | 15 | 15 | 64 |
| Type II Diabetes(participants) | T80+A10 | Telmisartan 80 mg | Amlodipine 10 mg | Total |
|---|---|---|---|---|
| No | 349 | 183 | 197 | 729 |
| Yes | 72 | 34 | 23 | 129 |
3 further baseline measures are reported on the registry.
Showing the first 100 of 137 sites across 11 countries. Choose a country and city above to see the rest.
The record gives a start of Mar 2009 and a primary completion of Dec 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2011, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Telmisartan · Amlodipine